[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Second Hospital of Shandong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":324},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,72,99,127,151,174,192,213,235,255,277,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100643080","the-application-of-hcg-in-luteal-support-for-frozen-embryo-transfer-in-ovulation-cycle-of-obese-women-100643080",false,"NCT07633002","The Application of HCG in Luteal Support for Frozen Embryo Transfer in Ovulation Cycle of Obese Women","The Application of HCG in the Luteal Support of Frozen Embryo Transfer During Ovulation Cycles in Overweight and Obese Women","Inclusion Criteria:\n\n* Age ≤37 years old ② Prepare the endometrium in the natural cycle\u002Fovulation induction cycle ③ BMI≥24 according to the overweight standard for the Asian population ④ Single blastocyst transfer (including IVF and ICSI-assisted pregnancy) ⑤ At least one frozen blastocyst remaining in the IVF\u002FICSI cycle with a Gardner morphology score of ≥4BC, and the age of the frozen embryo is D5 or D6\n\nExclusion Criteria:\n\n* There is a history of adenomyosis, hydrosalpinx, intrauterine adhesions or untreated submucosal fibroids of the uterus\n\n  * Uterine malformations; ③ The endometrial thickness on the conversion day is less than 7mm, or the cycle was cancelled during the endometrial preparation process before frozen embryo transfer due to the endometrium being less than 7mm in the past.\n\n    * Have a history of the immune system, such as antiphospholipid syndrome\u002Fsystemic lupus erythematosus\u002Frheumatism; ⑤ Diabetic patients who have not been controlled by standardized medication; ⑥ Those who have undergone embryo transfer more than or equal to two times without achieving a live birth ⑦ Those whose embryos to be thawed and thawed are from donated or frozen egg sources, or have undergone two freezing operations",true,"FEMALE","22 Years","37 Years",{"count":21,"type":22},750,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to explore whether the application of low-dose HCG in luteal support can improve the pregnancy outcomes of natural cycle frozen embryo transfer in obese patients",[28],"Obesity, Maternal",[30],"obesity,IVF-ET,Frozen embryo transfer","NOT_YET_RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-08","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2027-12-31",{"name":41,"class":42},"The Second Hospital of Shandong University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100626049","adebrelimab-combined-with-chemotherapy-for-the-esophageal-squamous-cell-carcinoma-100626049","NCT07430579","Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","A Single-arm, Single-center, Exploratory Clinical Study of Adebrelimab Combined With Neoadjuvant Chemotherapy for the Treatment of Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Patients must have a histopathologically confirmed diagnosis of Esophageal Squamous Cell Carcinoma （ESCC）.\n2. Eligible patients are those with stage II\u002FIII disease according to the AJCC\u002FUICC 8th edition Tumor-Node-Metastasis (TNM) staging system, presenting with cT1-3N1-2M0 or cT3-4aN0M0 disease.\n3. Patients could tolerate chemotherapy and surgery after evaluation and MDT discussion, accepting the clinical trial protocol.\n\nExclusion Criteria:\n\n1. Patients with a history of other uncured malignancies within the past 5 years, individuals with ongoing or a history of autoimmune diseases, and those who have received any prior anti-tumor therapy.\n2. Patients' cardio- pulmonary function could not tolerate surgery or chemotherapy, or don't accept the clinical trial protocol.","ALL","18 Years","80 Years",{"count":54,"type":22},25,[25],"This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant therapy with adebrelimab combined with platinum-based chemotherapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) at the Second Qilu Hospital of Shandong University.\n\nThe primary endpoint of this clinical trial is the pathological complete response (pCR) rate, defined as the absence of residual viable tumor cells in the resected specimen, including lymph nodes (ypT0N0M0). Secondary endpoints include the major pathological response (MPR) rate, objective response rate (ORR), treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs), as well as quality of life (QOL) assessments during neoadjuvant immunochemotherapy (nICT). MPR is defined as less than 10% residual viable tumor cells in the primary tumor bed following neoadjuvant therapy and resection. ORR represents the percentage of patients achieving complete response (CR) or partial response (PR). Other secondary measures include the tumor downstaging rate, surgery rate, R0 resection rate (defined as no residual tumor at the resection margins), and perioperative complication rate. Furthermore, overall survival (OS) and relapse-free survival (RFS) are considered exploratory endpoints in this study. By evaluating these diverse endpoints, the investigators aim to comprehensively assess the efficacy, safety, and overall impact of the nICT approach in patients with locally advanced resectable ESCC. Additionally, it is planned to construct 20 pairs of esophageal squamous cell carcinoma and adjacent normal esophageal squamous epithelial organoids, laying the groundwork for future in-depth exploration of the mechanisms underlying esophageal carcinogenesis and progression, as well as functional studies of specific genes.",[58,59,60,61],"Pathological Complete Remission","Objective Response Rate","Immune-related Adverse Events","Quality of Life","RECRUITING","2026-02-23",{"date":65,"type":35},"2026-02-24",{"date":67,"type":35},"2024-12-09",{"date":69,"type":22},"2028-06-30",{"name":41,"class":42},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":71},"100592227","phase-2-effect-of-salidroside-on-pregnancy-outcomes-in-high-childbearing-age-patients-in-viro-fertilization-100592227","NCT06990685","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization: an Open-label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥35 and \\\u003C 40 years old\n2. For the first or second cycle of IVF, ICSI or IVF with donor sperm\n3. According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC \\\u003C 5 or AMH \\\u003C 1.2ng\u002Fml (measured within the past half year) in both ovaries.\n\nExclusion Criteria:\n\n1. Patients with coagulation disorders\n2. Patients with previous abnormal uterine bleeding\n3. Combined with hydrosalpinx confirmed by B-ultrasound and HSG\n4. Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions\n5. Patients with previous spontaneous abortion ≥3 times\n6. Patients with contraindications to assisted reproductive technology or pregnancy\n7. Previous or current oral medication containing salidroside\n8. The controlled ovarian stimulation protocol included PPOS protocol, luteal phase ovulation induction protocol, and continuous stimulation protocol","35 Years","39 Years",{"count":82,"type":22},370,[84],"PHASE2","With the decreasing of birth rate and population in our country, population problem has become a long-term and strategic problem. In addition to the decrease in the number of women of childbearing age and the impact of unmarried women, the increase in the incidence of reproductive disorders and the delay of marriage and childbearing are also important factors leading to the continuous decline of the birth population in China. Among them, ovarian aging is a key factor causing female fertility difficulties. Therefore, establishing an effective prevention and treatment strategy for ovarian aging is of great significance for improving female reproductive health and serving the national population strategy. Recently, several supplements have been found to promote folliculogenesis and improve oocyte quality. However, to date, there is no approved therapeutic agent for the treatment of ovarian aging. Therefore, it is urgent to develop effective strategies for the prevention and treatment of ovarian aging.\n\nSalidroside is the main active component of Chinese medicine Rhodiola, and its content is highest in the root of rhodiola, which is also the main medicinal part. The main efficacy of salidroside in traditional Chinese medicine is to benefit qi, promote blood circulation, unblock pulse and relieve asthma. At the same time, in basic research, more and more experiments have shown that salidroside has a variety of pharmacological properties, including anti-hypoxia, anti-fatigue and anti-aging effects, anti-cancer, anti-inflammatory, anti-oxidation, antiviral and so on. These pharmacological effects suggest that salidroside may be an effective drug for the prevention and treatment of atherosclerosis, Parkinson's disease, Alzheimer's disease, pneumonia and other diseases. In terms of aging, it has been confirmed that salidroside supplementation can prolong the life span of pseudogill oryzias zhan and rescue premature aging of human skin fibroblasts, etc., which further confirms.\n\nThe aim of this study is to investigate the efficacy of salidroside as an adjuvant drug in improving the pregnancy outcomes of fresh embryo transfer in high childbearing age patients with poor ovarian response by comparing the pregnancy outcomes of fresh embryo transfer between salidroside group and blank control group. This pragmatic clinical study is expected to improve pregnancy outcomes of fresh embryo transfer cycles in women of advanced childbearing age with poor ovarian response.",[87,88,89,90],"Salidroside","Randomized Controlled Trial","In Vitro Fertilization","Assisted Reproductive Technology","2025-05-22",{"date":93,"type":35},"2025-05-25",{"date":95,"type":22},"2025-06-01",{"date":97,"type":22},"2027-12",{"name":41,"class":42},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":50,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":71},"100586481","epidemiological-study-of-osteoporosis-in-the-elderly-population-of-shandong-province-100586481","NCT06915935","Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province","Study on the Epidemiological Characteristics of Osteoporosis and the Diagnostic Significance of Bone Metabolic Biochemical Markers in the Elderly Population of Shandong Province","Inclusion Criteria:\n\n* Residents ≥65 years of age who had lived in the area for more than 6 months in the past 1 year\n\nExclusion Criteria:\n\n* People with cognitive impairment or mental illness","65 Years",{"count":108,"type":22},2000,"OBSERVATIONAL","At present, there is little epidemiological information on osteoporosis in the elderly population of Shandong Province, especially the lack of systematic research on the role of bone metabolism and biochemical indicators in the diagnosis and prognosis of osteoporosis in the elderly population of Shandong Province. The group intends to conduct a study on the epidemiological characteristics of osteoporosis patients and the significance of bone metabolism biochemical indexes in the diagnosis and prognosis of osteoporosis in elderly people in Shandong Province, which includes 1) assessing the prevalence of osteoporosis and the risk factors associated with osteoporosis in the community population, and 2) exploring the role of bone metabolism biochemical indexes in the diagnosis and prognosis of osteoporosis in the hospitalised population. Expected outcomes include the establishment of a database of community and inpatient populations in Shandong Province, publication of research papers, and participation in academic conferences at home and abroad. The database will collect and organise data on osteoporosis in the community and inpatient osteoporosis in Shandong Province, and provide support for subsequent data analysis and research.",[112,113],"Osteoporosis","Osteoporosis (Senile)",[115,116,117,118],"osteoporosis","epidemiology","elderly","Biochemical indexes of bone metabolism","2025-04-04",{"date":121,"type":35},"2025-04-08",{"date":123,"type":35},"2023-08-01",{"date":125,"type":22},"2026-01-31",{"name":41,"class":42},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":50,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":71},"100581318","tubeless-surgery-with-impaired-pulmonary-function-100581318","NCT06848751","Tubeless Surgery With Impaired Pulmonary Function","Non-intubated Thoracoscopic Surgery for Lung Leision in Patients With Impaired Pulmonary Function","Inclusion Criteria:\n\n1. Patients with impaired lung function (who may require postoperative intubation and transfer to the surgical ICU after preoperative and MDT discussions).\n2. Patients requiring minimally invasive lung resection due to lung cancer, pulmonary nodules, benign lung tumors, pneumothorax, lung volume reduction surgery, etc.\n3. Patients with normal mental status who can cooperate with perioperative examinations, exercises, and physical rehabilitation measures.\n4. Patients who agree to participate in the clinical trial after communication.\n\nExclusion Criteria:\n\n1. Patients with severe impairment of cardiopulmonary function or other organ systems, who are deemed unable to tolerate any form of anesthesia or minimally invasive surgery after preoperative and MDT discussions.\n2. Patients with abnormal mental status or who are unable to adequately cooperate with perioperative examinations, exercises, and physical rehabilitation measures.\n3. Patients who refuse to participate in the clinical trial or decline the use of non-intubated anesthesia with preserved spontaneous breathing.\n4. Patients who refuse to undergo surgery.","14 Years","85 Years",{"count":137,"type":22},30,[25],"Some patients with impaired lung function require minimally invasive surgical treatment, including those with lung cancer, benign lung tumors, pneumothorax, or lung volume reduction surgery. Patients with borderline lung function often cannot be extubated immediately postoperatively under conventional treatment models. These patients typically need to be transferred to the surgical ICU for close monitoring. However, positive-pressure mechanical ventilation with an endotracheal tube carries risks of further airway injury and persistent air leakage from the lung surface, leading to a high incidence of postoperative respiratory failure.\n\nNon-intubated minimally invasive surgery (tubeless), which preserves spontaneous breathing without endotracheal intubation, avoids the physical stimulation of intubation and the airway damage caused by mechanical ventilation. This approach may reduce the incidence of postoperative airway injury and respiratory failure, potentially expanding the indications for minimally invasive lung surgery, lowering postoperative complication and mortality rates.\n\nThe aim is to further clarify the surgical indications for non-intubated single-port minimally invasive surgery in patients with impaired lung function, the decision-making criteria for postoperative ICU transfer, and the safety and feasibility of this comprehensive management approach.",[141,142],"Lung Function Decreased","Surgery","2025-02-22",{"date":145,"type":35},"2025-02-27",{"date":147,"type":35},"2021-04-10",{"date":149,"type":22},"2026-12-31",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100542061","cpb-for-arthroscopic-hip-surgery-100542061","NCT06337968","CPB for Arthroscopic Hip Surgery","Circum-Psoas Block for Arthroscopic Hip Surgery: A Randomized Trial","Inclusion Criteria:\n\n* Primary unilateral ambulatory hip arthroscopy\n* Age 18 to 70 years\n* ASA physical status I to III\n* Ability to follow the protocol.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>70 years of age\n* BMI above 40\n* Contraindications to peripheral nerve blockade\n* Pregnancy\n* Chronic pain condition requiring opioid intake at home\n* Allergy to opioids or local anesthetics\n* Patient refusal","70 Years",{"count":160,"type":22},74,[25],"Arthroscopic hip surgery is being increasingly performed to treat both intraarticular and extraarticular hip diseases. Despite the minimally invasive approach, patients undergoing arthroscopic hip surgery still suffer severe pain due to the complex nature of hip innervation. Postoperative pain reduces patient satisfaction and delay patient recovery and discharge. The efficacy of regional anesthesia techniques in postoperative pain management have been proved in various surgeries. However, it remains controversial whether or not peripheral nerve blocks can significantly improve postoperative analgesia after hip arthroscopy.\n\nSeveral studies have shown that the fascia iliac block cannot improve postoperative analgesia for hip arthroscopy because it blocks only some branches of the lumbar plexus but not the sacral plexus. Circum-Psoas Block (CPB) which has been defined in recent years is able to block the lumbar plexus nerves as well as sacral plexus such as the sciatic, superior gluteal, and inferior gluteal nerves. Therefore, the investigators predict that it can provide effective postoperative analgesia for hip arthroscopy. In this study, the researchers aim to investigate the effectiveness of CPB in hip arthroscopy.",[164,165],"Acute Pain","Opioid Use","2024-11-21",{"date":168,"type":35},"2024-11-25",{"date":170,"type":22},"2024-12-01",{"date":172,"type":22},"2025-12-31",{"name":41,"class":42},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":50,"minAge":106,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":71},"100560550","perioperative-smoking-cessation-in-elderly-chinese-undergoing-spinal-fusion-100560550","NCT06578611","Perioperative Smoking Cessation in Elderly Chinese Undergoing Spinal Fusion","The Effects of Perioperative Smoking Cessation on Complications in Elderly Chinese Undergoing Spinal Fusion With Enhanced Recovery After Surgery: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Patients aged 65 years old or more;\n2. Patients who plan to undergo spinal fusion with ERAS program;\n3. Patients who agreed to participate in this study.\n\nExclusion Criteria:\n\n1. Patients who cannot understand the study content or have difficulty communicating;\n2. Patients with a history of spinal fusion surgery;\n3. Patients with spinal fractures, spinal tumor, or spinal infections;\n4. Patients with congenital spinal deformity;\n5. Patients who were unable to complete at least 6 months of follow-up;\n6. Patients with incomplete clinical information.",{"count":108,"type":22},"As China's society ages faster, the number of elderly patients undergoing spinal fusion surgery will gradually increase. Since elderly patients are at higher risk of postoperative complications than younger patients, minimizing complications after spinal fusion becomes a priority in postoperative rehabilitation. The purpose of this prospective cohort study is to develop an enhanced recovery after surgery program including individualized perioperative smoking cessation strategies in Chinese elderly undergoing spinal fusion.",[184],"Spinal Fusion","2024-08-28",{"date":187,"type":35},"2024-08-29",{"date":189,"type":22},"2024-09",{"date":97,"type":22},{"name":41,"class":42},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":16,"sex":50,"minAge":51,"maxAge":135,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":71},"100479861","self-reported-outcomes-of-patients-in-eras-nursing-100479861","NCT05528484","Self-reported Outcomes of Patients in ERAS Nursing","Effect of ERAS Nursing on Self-reported Outcomes of Patients Undergoing Minimally Invasive Lung Cancer Surgery","Inclusion Criteria:\n\n* ≥18years,Minimally invasive elective surgery,cooperate\n\nExclusion Criteria:\n\n* Pneumonectomy was performed and converted to open surgery\n\nSurgery intensive care, unable to cooperate (language\n\nSpeech disorders, psychopathology)",{"count":200,"type":22},600,[25],"We aimed to evaluate the effect of ERAS nursing program on self-reported outcomes of patients undergoing minimally invasive lung cancer surgery, and compared the differences in length of hospital stay, complications, and readmission rate between ERAS and non-ERAS nursing programs",[204],"Enhanced Recovery After Surgery","2022-11-14",{"date":207,"type":35},"2022-11-16",{"date":209,"type":35},"2019-10-01",{"date":211,"type":22},"2027-08-31",{"name":41,"class":42},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":50,"minAge":220,"maxAge":52,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":71},"100415374","ajuvant-chemotherapy-and-immunotherapy-in-patients-with-esophageal-esophageal--gastric-junction-cancer-100415374","NCT04688801","Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer","Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer With or Without Preoperative Chemotherapy With High Risk for Recurrence (N+ and\u002F or R1)","Inclusion Criteria:\n\nHistologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and lung function can tolerate surgery. The cancer is resectable and incurable therapy will be perfomed.\n\nExclusion Criteria:\n\nEG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection Status.","25 Years",{"count":222,"type":22},200,[25],"Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.",[226,227,228,229],"Esophageal Cancer","Gastroesophageal Cancer","Immunotherapy","Adjuvant",{"date":207,"type":35},{"date":232,"type":35},"2020-07-01",{"date":39,"type":22},{"name":41,"class":42},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":135,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":71},"100397157","lung-surgery-with-enhanced-recovery-vs-lung-surgery-without-enhanced-recovery-100397157","NCT04451473","Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery","The Short Term and Long Term Comparison of Lung Surgery With or Without Enhanced Recovery","Inclusion Criteria: patients with stage I-IIIa Non-small-cell Lung Cancer underwent radical resection or other benign lung lesions need VATS surgery.\n\n\\-\n\nExclusion Criteria: cardio-pulmonary function couldn't tolerate surgery\n\n\\-",{"count":243,"type":22},350,[25],"Objective: The adoption of Enhanced Recovery Surgery programs in lung resection is relatively recent with limited outcome data. This study aimed to determine the impact of an Enhanced Recovery Surgery pathway on short- term and long- term results in patients undergoing lung resection for primary lung cancer.\n\nMethods: A Randomized Controlled Trial was designed to collect the perioperative data on consecutive patients undergoing lung resection for primary lung cancer. Patients will be randomizely assigned to the ERAS- Group and Control- Group. Short-term and long- term effect will be compared between the two groups.",[247,142,248],"Lung Cancer","ERAS",{"date":207,"type":35},{"date":251,"type":35},"2019-10-08",{"date":253,"type":22},"2027-06-30",{"name":41,"class":42},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":50,"minAge":262,"maxAge":52,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":71},"100379660","video-assisted-thoracoscopic-thymectomy-versus-subxiphoid-procedure-100379660","NCT04223466","Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure","Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Thymectomy: Short- Term and Long- Term Results","Inclusion Criteria:\n\n1. Thymoma with or without myasthenia gravis；\n2. Generalized myasthenia gravis not sensitive to conservative medicine treatment;\n3. Good cardiopulmonary function.\n\nExclusion Criteria:\n\n1. Cardiopulmonary function can't bear surgery;\n2. Generalized myasthenia gravis with MuSK(+).","20 Years",{"count":264,"type":22},100,[25],"Surgerys used in thymectomy for myasthenia gravis and anterior mediastinal tumours have become much less invasive in recent years. In our study, the surgical technique which resected the thymus below the xiphoid process and the technique which was regarded as conventional video- assisted thoracoscopic surgery (VATS) thymectomy was compared.",[268],"Thymectomy",[270,271],"Video-assisted thoracoscopic surgery","Subxiphoid approach",{"date":207,"type":35},{"date":274,"type":35},"2020-01-07",{"date":39,"type":22},{"name":41,"class":42},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":135,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":71},"100476122","tubeless-intersegmentectomy-plane-identification-with-fluorography-100476122","NCT05479825","Tubeless Intersegmentectomy Plane Identification With Fluorography","Tubeless Intersegmentectomy Plane Identification With Inflation- Deflation Line Combined With Fluorography","Inclusion Criteria:\n\n1. cardio- pulmonary function can tolerate the minimally invasive surgery (including VATS and robotic surgery);\n2. benign pulmonary lesion considering for segmentectomy;\n3. ≤2cm pulmonary adenocarcinoma with ground- glass components, considering for segmentectomy.\n\nExclusion Criteria:\n\n1. cardio- pulmonary function can not tolerate the minimally invasive surgery (including VATS and robotic surgery);\n2. segmentectomy is not considered as the surgery plan.",{"count":285,"type":22},60,[25],"Background: We aimed to evaluate the combination of inflation- deflation method and fluorography with the ICG injection in the tubeless minimally invasive segmentectomy (no intubation, VATS or Robotic).\n\nMethods: A one- armed, prospective randomized controlled study was designed. The intersegmental plane was not so clear during the tubeless minimally invasive segmentectomy, and the presentation of the plane sometimes cost more time. This study will evaluate consecutive patients with the combination of inflation- deflation method and fluorography with the ICG injection.",[289,290],"Operation Time","Postoperative Complications","2022-07-28",{"date":293,"type":35},"2022-07-29",{"date":295,"type":35},"2022-01-01",{"date":297,"type":22},"2028-12-31",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":135,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":71},"100460053","robotic-versus-video-assisted-lobectomysegmentectomy-for-lung-surgery-100460053","NCT05270616","Robotic Versus Video-assisted Lobectomy\u002FSegmentectomy for Lung Surgery","Inclusion Criteria:\n\n1. good cardio- pulmonary function to tolerate surgery;\n2. minimaly invasive surgery for lobectomy or segmentectomy or sleeve lobectomy;\n\nExclusion Criteria:\n\n1. cardio- pulmonary function is not good enough to tolerate surgery;\n2. huge tumor or extensive adhesion in thoracic cavity.",{"count":306,"type":22},800,[25],"To compare the safety\u002Fefficacy of the robotic-assisted lobectomy\u002Fsegmentectomy (RAL\u002FS) with the video-assisted lobectomy\u002Fsegmentectomy (VAL\u002FS) for lung resection.\n\nVideo-assisted lobectomy\u002Fsegmentectomy (VAL\u002FS) for lung resection is divided into uniport group and multiple- port group.",[310,142],"Lung Diseases",[312,313,314,315],"robotic surgery","VATS","uniport","multiport","2022-02-27",{"date":318,"type":35},"2022-03-08",{"date":320,"type":35},"2020-06-01",{"date":322,"type":22},"2028-06-01",{"name":41,"class":42},""]